A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Enrolling by invitation

Conditions studied: Hematologic Malignancy, Solid Malignancy

In brief

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Key facts

Study ID
NCT06208878
Run by
CRISPR Therapeutics AG
People needed
70
Starts
2023-11-22
Expected to finish
2038-08-01
Last updated by the study team
2025-08-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.